[Clinical study of the use of "Spirolang" 50].
D000328:Adult; D000368:Aged; D001201:Ascites / Q000188:drug therapy*; D002908:Chronic Disease; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004231:Diuresis / Q000187:drug effects; D004573:Electrolytes / Q000378:metabolism; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy*; D006333:Heart Failure / Q000188:drug therapy*; D006349:Heart Valve Diseases / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011660:Pulmonary Heart Disease / Q000188:drug therapy; D013148:Spironolactone / Q000627:therapeutic use*
D004071:Digitalis Glycosides; D004573:Electrolytes; D013148:Spironolactone; D005665:Furosemide; D004976:Ethacrynic Acid
Contributo clinico all'uso dello "Spirolang" 50.